A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/1992
10/11/1992	CA2108152A1 Nitrosation of homocysteine as a method for treating homocysteinemia
10/11/1992	CA2107879A1 Proteinaceous lipid-containing particles
10/11/1992	CA2107682A1 Interleukin-8 receptors and related molecules and methods
10/11/1992	CA2065681A1 Method of producing hybridomas
10/11/1992	CA2065530A1 Saliva substitute
10/10/1992	CA2065585A1 Amidinophenylalanine derivatives, process for their preparation, their use and compositions containing them
10/09/1992	WO1992017591A1 A plant chitinase gene and use thereof
10/09/1992	WO1992017195A1 Novel peptide compositions and uses therefor
10/09/1992	CA2107674A1 Novel peptide compositions and uses therefor
10/09/1992	CA2048696A1 Plant chitinase gene and use thereof
10/09/1992	CA2048477A1 Plant chitinase gene and use thereof
10/07/1992	EP0507573A2 Readily absorbable motilin preparations
10/07/1992	EP0507555A1 Use of rapamycin for treating diabetes
10/07/1992	EP0507484A1 A pharmaceutical formulation of aureobasidins
10/07/1992	EP0507348A2 Superoxide dismutase derivatives
10/07/1992	EP0507187A1 Method for inhibiting pulmonary oxygen toxicity
10/07/1992	EP0507179A2 Equine herpes viruses (EHV) containing foreign DNA, process for their preparation and their use as vaccines
10/07/1992	EP0506971A1 Peptide with activity of inhibiting phospholipase a2 originating in inflamed part
10/07/1992	EP0506963A1 Production of human basic fgf mutein
10/07/1992	EP0506956A1 External preparation for skin
10/07/1992	EP0506893A1 Diagnosis and treatment of diseases
10/07/1992	EP0506890A1 Recombinant thyrotropin receptor
10/07/1992	EP0506868A1 Immunologically active proteines from borrelia burgdorferi, related test kits and vaccine.
10/07/1992	EP0506855A1 Cytokine antibody for the treatment of sepsis
10/07/1992	EP0506854A1 An improved toxin for construction of immunotoxins
10/07/1992	EP0506840A1 Method of treating ocular diseases by periocular administration of cyclosporine a or g
10/07/1992	EP0506821A1 Hybrid protein c
10/07/1992	EP0506820A1 Neutrophil chemoattractants
10/07/1992	EP0506792A1 Insulin preparations containing nicotinic acid or nicotinamide.
10/07/1992	EP0506785A1 Improved treatment of autoimmune diseases by aerosol administration of auto antigens
10/07/1992	EP0506769A1 Pharmaceutical composition for treating or preventing retroviral infections.
10/07/1992	EP0506757A1 A recombinant human factor viii derivative
10/07/1992	EP0506755A1 Polypeptides having serine protease inhibitor activity and dna coding therefor
10/07/1992	EP0493380A4 Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs
10/07/1992	EP0213180B1 Neovascularization inhibitors and methods for their production and use
10/07/1992	EP0201579B1 Preparations containing a microflora having increased adhesive effect
10/07/1992	CN1065019A Process for preparing pharmaceutically composition containing polypeptides
10/07/1992	CN1064983A Improved fish production
10/06/1992	WO1992017492A1 PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a?
10/06/1992	USRE34090 Polypeptide cartilage-inducing factors found in bone
10/06/1992	US5153358 Alkylating a 3-substituted-10bH-oxazolo(3,2-c)(1,3)-benzoxazine-2(3H),5-dione follwed by treatment by an acid or base to effect decyclization and hydrolysis
10/06/1992	US5153310 Il-2 analogs containing n-linked glycosylation sites
10/06/1992	US5153308 S-sulfonated calcitonin derivatives
10/06/1992	US5153265 Conjugation of polymer to colony stimulating factor-1
10/06/1992	US5153176 Substituted lysine-proline-arginine peptide
10/06/1992	US5153175 Method of inducing sleep with GHRH complementary peptide compositions
10/06/1992	US5153173 N-acyl derivatives of the peptidoglycan monomer, pharmaceutically acceptable salts thereof, their preparation and use as immunomodulators and immunoadjuvants
10/06/1992	US5153118 Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
10/06/1992	US5152982 Compositions and methods for FeLV vaccination
10/06/1992	US5152979 Method for treating vascular obstructions caused by abnormal cells
10/06/1992	US5152758 Electroresponsive hydrogel and physiologically active substance release control system
10/06/1992	CA2106314A1 Platelet aggregation inhibitors having high specification for gpiibiiia
10/06/1992	CA1308515C Peptide derivatives and processes for their preparation
10/06/1992	CA1308377C Complex of polyethyleneglycol and tissue plasminogen activator
10/05/1992	WO1992017203A1 Enzymatic neutralization of heparin
10/04/1992	CA2064678A1 Method of treating diabetes
10/04/1992	CA2064635A1 Stimulation of growth with anti-idiotypic antibodies raised against an antibody to a growth potentiating polypeptide
10/03/1992	CA2063968A1 Pharmaceutical formulation of aureobasidins
10/02/1992	CA2064413A1 Anti-idiotypic monoclonal antibodies
10/02/1992	CA2064149A1 Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
10/01/1992	WO1992017025A2 GnRH ANALOGS
10/01/1992	WO1992016837A1 Detection and treatment of ulcerative colitis
10/01/1992	WO1992016660A1 Methods for detection and treatment of cancer
10/01/1992	WO1992016638A1 Transduction vehicles for transferring dna to a mammalian cell
10/01/1992	WO1992016626A1 Equine epidermal growth factor
10/01/1992	WO1992016624A1 Monoclonal antibody against lps core
10/01/1992	WO1992016620A1 Human follicle stimulating hormone receptor
10/01/1992	WO1992016619A1 Expression of influenza nucleoprotein antigens in baculovirus
10/01/1992	WO1992016563A1 Monoclonal antibodies recognizing lymphocyte function associated antigen-3
10/01/1992	WO1992016561A1 Ovine adipocyte antigens and their use in the immunological control of fat
10/01/1992	WO1992016560A1 Cns cell differentiation factor, its preparation and use
10/01/1992	WO1992016557A1 Recombinant human factor viii derivatives
10/01/1992	WO1992016553A1 Monoclonal and chimeric antibodies specific for human tumor necrosis factor
10/01/1992	WO1992016552A1 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity
10/01/1992	WO1992016549A1 Parasubstituted phenylalanine derivates
10/01/1992	WO1992016547A1 Controlling nk-1 receptor-mediated responses and related diagnostics
10/01/1992	WO1992016524A1 Benzo-fused lactams promote release of growth hormone
10/01/1992	WO1992016232A1 Polysaccharide-protein conjugates
10/01/1992	WO1992016229A1 Products containing verapamil and trandolapril
10/01/1992	WO1992016227A1 Use of apotransferrin which has accumulated zinc or copper ions to combat the toxic action of endotoxin
10/01/1992	WO1992016226A1 Il-1 inhibitors
10/01/1992	WO1992016225A1 Antiplatelet and antithrombotic activity of platelet glycoprotein ib receptor fragments
10/01/1992	WO1992016220A1 Controlling nk-2 receptor-mediated responses and relates diagnostics
10/01/1992	WO1992016212A1 Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
10/01/1992	WO1992016203A1 Palytoxin-related prodrugs and a method for their administration
10/01/1992	WO1992016181A2 Composition for promoting tissue repair and regeneration
10/01/1992	DE4110422A1 Arzneimittel enthaltend humanes corticotropin-releasing hormon (crh) und/oder dessen derivate und/oder glucocorticoide natuerlicher und/oder synthetischer provenienz A medicament comprising human corticotropin-releasing hormone (CRH) and / or its derivatives and / or glucocorticoids natural and / or synthetic origin
09/1992
09/30/1992	WO1992017586A1 Protein having a cytokinin-type activity, recombinant dna coding for this protein, transformed cells and micro-organisms
09/30/1992	WO1992017570A1 Virus inactivation method and pharmaceutical composition therefor
09/30/1992	WO1992017077A2 Fat substitute compositions having reduced laxative effects
09/30/1992	EP0506651A2 Pharmaceutical preparation based on plasma proteins
09/30/1992	EP0506628A2 Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances
09/30/1992	EP0506574A1 Protein having cytokin type activity, recombinant DNA coding for this protein, transformed cells and microorganisms
09/30/1992	EP0506477A1 Vascular endothelial cell growth factor C subunit
09/30/1992	EP0506326A2 Diequitorially bound beta 1-4 polyuronates and use of same for cytokine stimulation
09/30/1992	EP0506124A1 Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules
09/30/1992	EP0505966A1 Long-acting biodegradable microparticles and process for preparation
09/30/1992	EP0505954A1 N-Imidazolylmethyl benzofuran derivatives as inhibitors of angiotensin II activity
09/30/1992	EP0505941A2 Peptifluorin and neopeptifluorin
09/30/1992	EP0505908A1 Chimaeric polypeptides

1 ... 2960 2961 2962 2963 2964 2965 2966 2967 2968 2969 2970 2971 2972 2973 2974 2975 2976 2977 2978 2979 2980 ... 3163